A recent study reveals that individuals who stop using blockbuster GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight far faster than those who end traditional diet and exercise programs.
Findings released in a leading medical journal shows that while overweight individuals frequently drop about a fifth of their body weight while on the medication, the mass is regained at an estimated rate of nearly a kilo each month once they quit.
"Users buying these drugs must be aware of the risk of quick weight regain when the therapy is stopped," stated lead investigator Dr. Susan Jebb.
That rate of regain suggests a reversion to original weight in about a year and a half.
Analyzing Therapies
The analysis, which reviewed dozens of trials involving thousands of participants, contrasted the outcomes of the injectable medications with older methods.
The team point out that people who shed pounds through dieting usually experience a slower weight regain—approximately 0.1 kg a month—after stopping.
Explaining the Quick Rebound
Doctors believe the mode of action of the injections explains the heightened rebound.
These medications copy a natural hormone called GLP-1, which controls appetite.
"Sustained high doses of the hormone levels far above than the body's typical production may cause the system to produce less of its endogenous GLP-1, and may also reduce sensitivity to its actions," noted Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this GLP-1 'fix' leads to appetite is no longer kept in check, making overeating far more likely."
A Chronic Disease?
The NHS recommend the jabs for individuals with obesity-related medical conditions, accompanied by recommended lifestyle changes.
Many experts say that, due to the likelihood of relapse, the treatment is often ongoing.
This perspective is supported by drug manufacturers, who note that the results "highlight the persistent nature of excess weight," akin to managing conditions like diabetes.
Patient Accounts
Individuals who have discontinued the jabs report a intense resurgence of cravings.
"It felt as if something flipping and I was suddenly ravenous," recalled one woman.
This challenge is worsened if individuals have not developed lasting dietary or behavioural changes during therapy.
Significant Interest
Recent estimates indicate that a significant number of adults in the UK have used weight-loss jabs in the last 12 months, with desire remaining high.
- Use is greater among women compared to men.
- The middle-aged demographic shows the greatest level of interest.
- Many access the drugs through private healthcare rather than public health services.
Finally, researchers caution that while GLP-1 drugs are effective tools for weight loss, they are not a standalone cure and maintained weight loss relies on integrated behavioural support.
